|
CGRRF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.89392945770805E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.66895402947875E-12 |
| Normal-vs-Stage2 |
1.025040E-04 |
| Normal-vs-Stage3 |
1.17073017946723E-12 |
| Normal-vs-Stage4 |
5.20228304878856E-12 |
| Stage1-vs-Stage2 |
2.547000E-01 |
| Stage1-vs-Stage3 |
1.714790E-01 |
| Stage1-vs-Stage4 |
5.593900E-02 |
| Stage2-vs-Stage3 |
5.963600E-02 |
| Stage2-vs-Stage4 |
1.914030E-02 |
| Stage3-vs-Stage4 |
4.341000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.73117076229801E-12 |
| Normal-vs-AfricanAmerican |
2.99039999995809E-06 |
| Normal-vs-Asian |
2.16289997023722E-09 |
| Caucasian-vs-AfricanAmerican |
7.454000E-01 |
| Caucasian-vs-Asian |
6.052800E-01 |
| AfricanAmerican-vs-Asian |
9.786200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.32116539930394E-13 |
| Normal-vs-Female |
4.31299440606381E-12 |
| Male-vs-Female |
1.035610E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.28517246528781E-12 |
| Normal-vs-Age(41-60Yrs) |
3.86080056813398E-11 |
| Normal-vs-Age(61-80Yrs) |
1.21630483462809E-11 |
| Normal-vs-Age(81-100Yrs) |
2.759500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.216600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.733400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.509600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.428200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.845800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.855600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.261350E-03 |
| Classical-VS-Follicular |
2.143200E-01 |
| Classical-VS-Other |
8.676200E-01 |
| Classical-VS-Normal |
1.1477041539365E-11 |
| Tall-VS-Follicular |
6.165500E-04 |
| Tall-VS-Other |
3.783200E-01 |
| Tall-VS-Normal |
3.28048699316241E-12 |
| Follicular-VS-Other |
6.113200E-01 |
| Follicular-VS-Normal |
1.73423999999534E-05 |
| Other-VS-Normal |
3.577400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.35800037881495E-10 |
| Normal-vs-N1 |
3.96349619791181E-14 |
| N0-vs-N1 |
2.035200E-03 |
|
|
